[go: up one dir, main page]

MX375925B - Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal. - Google Patents

Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.

Info

Publication number
MX375925B
MX375925B MX2016015248A MX2016015248A MX375925B MX 375925 B MX375925 B MX 375925B MX 2016015248 A MX2016015248 A MX 2016015248A MX 2016015248 A MX2016015248 A MX 2016015248A MX 375925 B MX375925 B MX 375925B
Authority
MX
Mexico
Prior art keywords
sup
treatment
muscular atrophy
spinal muscular
pyrazin
Prior art date
Application number
MX2016015248A
Other languages
English (en)
Other versions
MX2016015248A (es
Inventor
Emmanuel Pinard
Hasane Ratni
Luke Green
Patrick Williamson
Original Assignee
F Hoffmann La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche Ag filed Critical F Hoffmann La Roche Ag
Publication of MX2016015248A publication Critical patent/MX2016015248A/es
Publication of MX375925B publication Critical patent/MX375925B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona compuestos de fórmula (I) en donde A, X1, X2, R1, R2, R3, R4 y R5 son como se describe en el presente documento, así como sales farmacéuticamente aceptables de los mismos. Además, la presente invención se refiere a la fabricación de los compuestos de fórmula (I), composiciones farmacéuticas que los comprenden y su uso como medicamentos para el tratamiento de la atrofia muscular espinal.
MX2016015248A 2014-06-25 2015-06-22 Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal. MX375925B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14173935 2014-06-25
PCT/EP2015/063894 WO2015197503A1 (en) 2014-06-25 2015-06-22 Imidazo[1,2-a]pyrazin-1yl-benzamide compounds for treating spinal muscular atrophy

Publications (2)

Publication Number Publication Date
MX2016015248A MX2016015248A (es) 2017-02-23
MX375925B true MX375925B (es) 2025-03-07

Family

ID=50980240

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015248A MX375925B (es) 2014-06-25 2015-06-22 Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.

Country Status (10)

Country Link
US (1) US9975900B2 (es)
EP (1) EP3160967B1 (es)
JP (1) JP6675334B2 (es)
KR (1) KR102565544B1 (es)
CN (1) CN106459067B (es)
BR (1) BR112016026951B1 (es)
CA (1) CA2952895C (es)
MX (1) MX375925B (es)
RU (1) RU2725979C2 (es)
WO (1) WO2015197503A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2016109324A (ru) 2013-08-19 2017-09-26 Ф. Хоффманн-Ля Рош Аг Способ скрининга
US10874672B2 (en) 2015-12-10 2020-12-29 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
KR20200033249A (ko) 2017-06-05 2020-03-27 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료 화합물
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
CA3067592A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
JP7304855B2 (ja) * 2017-11-14 2023-07-07 ザ チルドレンズ メディカル センター コーポレーション 新規イミダゾピリミジン化合物およびそれらの使用
EP3710007A4 (en) 2017-11-14 2021-12-15 Children's Medical Center Corporation USE OF IMIDAZOPYRIMIDINE TO MODULATE A HUMAN IMMUNE RESPONSE
CA3094703A1 (en) 2018-03-27 2019-10-03 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
IL279786B2 (en) 2018-06-27 2025-02-01 Reborna Biosciences Inc Preventive or therapeutic agent for spinal muscular atrophy
WO2020005882A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
SG11202012674PA (en) 2018-06-27 2021-01-28 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for treating huntington's disease
KR20210038845A (ko) 2018-06-27 2021-04-08 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로아릴 화합물
MA54755A (fr) * 2019-01-18 2021-11-24 Biogen Ma Inc Dérivés d'imidazo[1,2-a]pyridinyle servant d'inhibiteurs d'irak4
WO2021007378A1 (en) 2019-07-11 2021-01-14 Ptc Therapeutics, Inc. Compounds for use in treating huntington's disease
KR20230028269A (ko) 2020-05-13 2023-02-28 씨에이치디아이 파운데이션, 인코포레이티드 헌팅턴병을 치료하기 위한 htt 조절제
WO2023283372A1 (en) * 2021-07-07 2023-01-12 Biogen Ma Inc. Compounds for targeting degradation of irak4 proteins
WO2023102231A1 (en) * 2021-12-03 2023-06-08 Rgenta Therapeutics, Inc. 5-pyrimidinecarboxamide derivatives and methods of using the same
TW202446260A (zh) 2023-04-13 2024-12-01 瑞士商先正達農作物保護股份公司 咪唑并［１，２－ａ］吡𠯤衍生物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005085252A1 (en) * 2004-03-04 2005-09-15 Biofocus Discovery Limited Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases
BRPI0811065A2 (pt) * 2007-06-08 2014-12-02 Abbott Lab Indazóis 5-heteroaril substituídos como inibidores de quinase
ES2556458T3 (es) * 2010-12-17 2016-01-18 Bayer Intellectual Property Gmbh 6-Imidazopirazinas sustituidas para uso como inhibidores de Mps-1 y TKK en el tratamiento de trastornos hiperproliferativos
MX352861B (es) * 2011-12-30 2017-12-13 Ptc Therapeutics Inc Compuestos para tratar la atrofia muscular espinal.
US9193723B2 (en) * 2012-05-11 2015-11-24 Abbvie Inc. NAMPT inhibitors
GB201212513D0 (en) * 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
AU2013289938A1 (en) * 2012-07-13 2015-01-29 Indiana University Research & Technology Corporation Compounds for treatment of spinal muscular atrophy
WO2014078813A1 (en) * 2012-11-19 2014-05-22 Irm Llc Compounds and compositions for the treatment of parasitic diseases
CN105358151B (zh) * 2013-06-25 2019-04-12 豪夫迈·罗氏有限公司 用于治疗脊髓性肌萎缩的化合物

Also Published As

Publication number Publication date
EP3160967B1 (en) 2019-05-08
RU2017102014A (ru) 2018-07-27
JP2017520570A (ja) 2017-07-27
KR102565544B1 (ko) 2023-08-10
BR112016026951B1 (pt) 2022-09-20
RU2017102014A3 (es) 2019-01-22
CN106459067A (zh) 2017-02-22
MX2016015248A (es) 2017-02-23
CN106459067B (zh) 2019-05-31
JP6675334B2 (ja) 2020-04-01
WO2015197503A1 (en) 2015-12-30
US9975900B2 (en) 2018-05-22
US20170197969A1 (en) 2017-07-13
RU2725979C2 (ru) 2020-07-08
CA2952895A1 (en) 2015-12-30
BR112016026951A2 (es) 2017-08-15
CA2952895C (en) 2023-09-26
KR20170018076A (ko) 2017-02-15
EP3160967A1 (en) 2017-05-03

Similar Documents

Publication Publication Date Title
MX375925B (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
MY174284A (en) Compounds for treating spinal muscular atrophy
MX2018005890A (es) Composiciones para tratar atrofia muscular espinal.
MX2015017345A (es) Compuestos para tratar atrofia muscular espinal.
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
PH12017500281B1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
PH12018500061A1 (en) Oxysterols and methods of use thereof
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
TW201613864A (en) Novel compounds
MX376283B (es) Compuestos de imidazopiridazina.
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
MX340574B (es) Imidazo pirazinas.
CY1120602T1 (el) [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων
EA201692298A1 (ru) Производные карбоксамидов
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX379704B (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
NZ701103A (en) Solid state forms of n-((s)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide

Legal Events

Date Code Title Description
FG Grant or registration